Comparison of Ga-68-DOTATATE and Ga-68-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Kabasakal L., Demirci E., Ocak M., Decristoforo C., Araman A., Ozsoy Y., ...Daha Fazla

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, cilt.39, sa.8, ss.1271-1277, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 8
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00259-012-2123-y
  • Dergi Adı: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1271-1277
  • Anahtar Kelimeler: Neuroendocrine tumours, Somatostatin receptor, Ga-68-DOTATATE, Ga-68-DOTANOC, Octreotide, SOMATOSTATIN RECEPTOR SUBTYPE-2, GA-68-DOTA-TYR(3)-OCTREOTIDE PET, PROGNOSTIC-FACTORS, DOTA-NOC, SCINTIGRAPHY, BIODISTRIBUTION, RADIOMETALS, EXPRESSION, THERAPY, ANALOGS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Recent studies have suggested that positron emission tomography (PET) imaging with Ga-68-labelled DOTA-somatostatin analogues (SST) like octreotide and octreotate is useful in diagnosing neuroendocrine tumours (NETs) and has superior value over both CT and planar and single photon emission computed tomography (SPECT) somatostatin receptor scintigraphy (SRS). The aim of the present study was to evaluate the role of Ga-68-DOTA-1-NaI3-octreotide (Ga-68-DOTANOC) in patients with SST receptor-expressing tumours and to compare the results of Ga-68-DOTA-D-Phe(1)-Tyr(3)-octreotate (Ga-68-DOTATATE) in the same patient population.